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Abstract: Most immune responses associated with vaccination are controlled by specific T cells of a
CD4+ helper phenotype which mediate the generation of effector antibodies, cytotoxic T lymphocytes
(CTLs), or the activation of innate immune effector cells. A rapidly growing understanding of the
generation, maintenance, activity, and measurement of such T cells is leading to vaccination strategies
with greater efficacy and potentially greater microbial coverage.
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1. Introduction
Because it is a critical facet of vaccination, the continuing progress in the understanding of T cell
memory is enhancing the further development of efficacious, licensed vaccines. This Special Issue of
Vaccines is aimed at highlighting ways in which T cell memory may impact the immunogenicity, and
ultimately the efficacy, of vaccines that are already in use or in development. This editorial briefly
signposts some key concepts surrounding T helper (Th) memory cells without attempting to review
the literature, as this has been done elsewhere [1,2]. Many vaccines in use today continue to rely on old
manufacturing technology and development, and may be far from optimal in their immunogenicity
and efficacy. The primary targets for vaccination among the human population tend to be either
quite young or elderly and therefore suffer deficiencies in immune responses, such as immaturity
in infants and exhaustion in the elderly. These groups are likely to require vaccines and vaccination
regimens that efficiently deliver frequent, sustained, high doses of antigen, together with immune
activating agents such as adjuvants or live organisms. Several diseases—HIV, Hepatitis C, some
Flaviviruses, and Ebola virus, for example—have no licensed vaccines available to prevent or treat
them. Diseases such as malaria, tuberculosis (TB), and influenza, have vaccines (Mosquirix [3], Bacillus
Calmette-Guerin (BCG), and several influenza vaccines) but would benefit from improved vaccines.
Antibodies have conventionally been the desired outcome of vaccination, as they are powerful effector
immune responses capable of intercepting and neutralizing microbes and their components as well as
instigating destructive anti-microbial innate immune responses. The measurement of specific antibody
levels often provides a marker of immunogenicity and likely indicates protection from disease [4,5].
Many newer vaccines and vaccines in development are often designed to generate T cell responses
that have the potential to help the antibody response, have direct effector functions themselves,
or activate innate effector cells such as macrophages and neutrophils. These vaccines include conjugate
vaccines, recombinant antigens with adjuvants, recombinant antigen-encoding viruses, nucleic acids,
nanoparticles, and virus-like particles. Some vaccination regimens use combinations of vaccines, either
administered together or at differing time points (heterologous prime-boost regimens), in order to
generate optimal responses. The resulting antigen-specific T cell responses need to be of the appropriate
type involving: helper T cells (Th cells, expressing cytokines and co-stimulatory molecules), and/or
cytotoxic T lymphocytes (CTL), and with memory and homing capacity, and should not be exhausted
or anergised via negative feedback or immune checkpoints (Tables 1 and 2).
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Table 1. Effector T cell phenotypes (canonical markers, not exhaustive or mutually exclusive).
Features Th1 Th2 Th17 TFh Treg Th22 CTL
Secreted Molecules:
(function)
IFNγ, IL-2, TNFα IL-4, IL-5, IL-13,
IL-9
IL-17 A/F IL-21 +/-IL-10, TGFβ IL-22 IFNγ, lytic
enzymes
Microbial
Target/location: intra-MΦ parasites extracellular all - epithelial intracellular
CXCR3 (inflammation) + +
CCR4 (CC chemokines) + +/−
CCR6 (mucosal) +
CCR5 (inflammation) +
CD161 (NK cell receptor) +
CCR10 (skin homing) +
CD25 (IL-2Rα) +hi
CXCR5 (B cell homing) +
PD-1 (inhibitory) +
Others ICOS, CD40L, OX40 TIM-3, LAG-3
Transcription factors Tbet, STAT1/4 GATA-3, STAT6 RORγt, STAT3 Bcl-6 FoxP3, STAT5 AHR Eomes, RUNX3
R in a name in “Features” indicates “receptor” for chemokine, controlling homing; MΦ: macrophage; Th: Helper T cell; Treg: regulatory T cell; CTL: cytotoxic T lymphocyte; TFh: follicular
helper cell.
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Table 2. Memory T cells (canonical markers, not exhaustive or mutually exclusive).
Markers Function TN TEM TEMRA/TE TCM TSCM TRM Exhausted T Cell
CD45RA signalling + − + − + +/−
CD45RO signalling − + − + − +/−
CD62L homing + −lo −lo + + −
IL-7Ra (CD127) proliferation + +/− − +hi + −
CD95 cell death − +hi +hi +hi + +
CCR7 homing +hi −lo −lo +hi + −
CD103 (αE) epithelial homing − + +
CD69 activation − +/− + − − +
CD28 costimulation +int lo −lo +hi + +/− −
CD27 costimulation +hi +/− − + +
CXCR3 inflammation − − − + + +
CD57 differentiation − +/− + − − +
PD-1 inhibitory − + +/− − +/− +
TN: Naïve; TEM: effector-memory; TEMRA: RA+ effector memory; TE: effector; TCM: central memory; TSCM: stem
cell memory; TRM: resident memory.
Ultimately, a correct formulation (antigen, vehicle, adjuvants; proportions thereof) and regimen
(including the number and interval between immunizations, and route of vaccination) that generates
the appropriate T cell response will be required. The measurement and characterization of these
T cells, although challenging, provides useful markers of immunogenicity and efficacy, and informs on
mechanisms for further vaccine development. There may or may not be a need for vaccines to emulate
T cell responses generated in natural protective immunity, particularly when selecting sequences in
antigens that are prone to mutation or variability for inclusion in novel vaccines, as is the case for HIV
and influenza. Innate immunity also impinges on the vaccine-induced priming, boosting, and effector
processes [6]. Effector lymphocytes with invariant T cell receptors or innate lymphoid cells and natural
killer (NK) cells are likely to be involved. Indeed, it has been shown that innate immune memory does
exist [7], the manipulation of which could be incorporated into vaccines. Finally, factors (other than
age) associated with the target population for vaccination are important to consider. These factors
include comorbidities, geographic factors (including microbial endemicity), nutritional status, and
iatrogenic immune suppression. Thus, a highly multi-faceted approach to vaccine design is required,
particularly for the currently non-tractable pathogens.
2. Human T Cell Effector and Memory Phenotypes
T cell memory can be defined as the collective reactivity of a population of T cells that respond
to a cognate antigenic challenge—an antigen that is recognized by their T cell receptors (TcRs).
This response occurs some time after the initial antigen exposure, by proliferating and/or expressing
molecules that are able to mediate an effector reaction. In vivo, meaningful memory equates to
protection from infection and/or disease when challenged with an infectious microbial pathogen,
either naturally or experimentally. T cell memory follows initial antigenic exposure and priming,
where naïve T cells (TN) respond to antigenic peptides complexed to major histocompatibility
complex (MHC) molecules on antigen-presenting dendritic cells (DCs). The context in which the
DCs encounter the antigen is imparted through their detection of vaccine-associated signals, e.g.,
toll-like receptor (TLR) ligands, which condition the DCs to express molecules such as IL-12. These
molecules influence the phenotype of the T cells, e.g., Th1 cells, when recognizing the presented
antigen within secondary lymphoid tissues (SLT). The DCs must ligate co-stimulatory molecule
pairings, e.g., B7:CD28, that provide further signals to the T cells. This mediates their proliferation
and differentiation into Th phenotypes (Table 1). Thus, T cells are programmed to possess particular
phenotypes that allow them to address the microbial challenges they are specifically designed to
combat, both antigenically and phenotypically. The phenotype is programmed epigenetically in the
resulting T cells through the expression of transcription factors, which are retained during homeostatic
non-antigenic-driven proliferation, controlled by growth factors, such as IL-2, IL-7 and IL-15, within
anatomical niches. In addition to their specificity and phenotype, T cells often need to retain surface
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receptors that promote their homing to regions where they were primed and are needed, such as the
mucosa (CCR6), the skin (CCR10), or the B cell region of SLT (CXCR5). Along with their effector
phenotype, T cells can be identified on the basis of their memory status (Table 2). CD45RA+ TN
cells possess molecules that facilitate their entry into SLT, namely, CD62L and CCR7, where they
become primed by cognate-antigen-presenting and activated DCs. After being primed, they proliferate
to become effector-memory T cells (TEM), losing the molecules for SLT retention and CD45RA in
the process. The TEM circulate within the peripheral blood mononuclear cells (PBMCs) and have
the ability to rapidly respond (sometimes within minutes) to the previously encountered antigens
within inflamed tissues. During antigenic recall, e.g., booster vaccination, Th cells demonstrate
some plasticity in their effector phenotype and can be redirected [8,9]. Once these cells respond,
memory T cells—particularly CD8+—regain CD45RA, becoming TEMRA/TE, and secrete effector
molecules. These effector molecules are particularly efficacious against intracellular pathogens with
short incubation periods and fast reproduction (mainly viruses). These T cells upregulate molecules
such as PD-1 and CD95, which makes them prone to inhibition and apoptosis, respectively. The purpose
of this is to maintain non-inflammatory cellular homeostasis once the threat (and associated antigen,
if indeed it is possible [10]) has subsided. Some of the TEM become resident T memory cells (TRM)
within the tissues [11,12] where the antigen is encountered and are again poised to rapidly respond to
a challenge, although their life spans may be short. TRM are kept in tissues by epithelial tissue-binding
CD103, and CD69 which antagonizes the migratory function of S1PR1 in T cells and allows lymphoid
memory deposits to persist. “Prime-and-trap” vaccines are being developed to specifically target
TRM generation [13]. A proportion of the primed cells become central memory T cells (TCM), which
re-express the SLT-homing receptors. These cells provide a population of circulating quiescent cells
that can respond to the re-encounter with an antigen within activated SLT by proliferating and
differentiating into TEM and TE cells over the course of some days. These TCM are therefore considered
better suited to protect against pathogens with longer incubation periods, such as certain parasites [14].
Some T cells take on stem cell-like features (TSCM) to provide very long-lived memory, often residing
in the bone marrow [15]. Within the SLT, follicular T helper cells (TFH) are generated. These cells are
attracted to B cells via CXCR5 and help B cells to produce class-switched and high-affinity antibodies
specific to their mutual cognate antigen through ligation via OX40, CD40L, and ICOS, as well as
through secretion of IL-21 [16,17]. The B cells act as the antigen-presenting cells (APCs) for the cognate
TSCM by the uptake of an antigen bound to their surface antibodies. Individuals with particular
immunodeficiencies provide insight into the importance of such T cell help in generating effective
antibodies and protection from infectious diseases [18].
3. Measurement of Vaccine-Associated T Cells
The ability to measure memory T cells in association with vaccination [19] is important to establish
a vaccine’s immunogenicity and may be a biomarker of efficacy by having a positive association with
protection from infection and/or disease [3,4]. Important factors in the measurement of T cell responses
are the methods of measurement, when to make these measurements, and in which locations. T cell
responses measured in the circulating PBMCs during a vaccination regimen tend to follow the typical
pattern of adaptive immune response, i.e., an initial exposure is followed by a lag phase, then a peak
in the response (such as an antigen-specific IFNγ response) at about one to two weeks, that eventually
settles back down to a response raised over the naïve response. Due to memory generated by the
priming, a second exposure through boosting gives a more rapid, greater response. Through TE
attrition [20], this response then settles to a level higher than it was before the boost. Thus, the aim of
boosting is to cause the T cells to reach a putative “protective” level. To date, few direct correlations
between T cell responses and degrees of protection from infection and disease have been established
for clinical use. “QuantiferonTM” and ELIspot tests have been able to detect latent Mycobacterium
tuberculosis infection in at-risk individuals through the detection of IFNγ secretion by peripheral
T cells reactive to particular TB antigens. However, such responses following vaccination for TB have
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not been associated with protection from infection [21], although a new vaccine has recently shown
efficacy [22]. Even if the PBMC may not be the ideal location to detect the reactive T cells that need to
act in specific tissues (such as the mucosa), precursors in transit (such as TEM and TCM) are measurable
with specialized or modified techniques. Ex vivo techniques on whole blood or PBMC involve the
exposure to the vaccine antigen and the measurement of responses, which typically occur within
one day. The most common of such tests involves bulk cytokine secretion from blood cells (whole
blood assay/ELISA) and cytokine measurement by flow cytometry and enzyme-linked immunospot
(ELISpot). This is done to identify responding cells at the single cell level. The expansion in the
number of available flow cytometry parameters means that cells can be identified as secreting or
expressing a multitude of molecules using single-cell mass cytometry and RNA sequencing, thus
allowing their characterization within effector phenotypes, memory phenotypes (Tables 1 and 2), and
beyond. Molecular signatures in blood that are associated with vaccination continue to implicate
T cells in protection [23]. Although it is more cumbersome, incorporating a period of culture of blood
cells with antigens and other factors allows specific memory cells like TCM to be revealed, as the culture
promotes differentiation to TEM and/or TE. One approach with whole blood that was cultured together
with a precise vaccine formulation (antigen in adjuvant + TLR ligand) [24] revealed significantly higher
T cell cytokine secretion. These results suggest that components of the whole blood interact with
components of the vaccine to promote T cell reactivation in a way that might emulate in vivo events.
Such an assay is capable of monitoring vaccine formulations for potency as well as testing vaccine
recipients for their potential to respond to a vaccine in vivo. Being able to emulate ectopic lymphoid
structures (memory depots) may provide one method of recreating and studying vaccine responses
in vitro.
4. Conclusions
Technological advances in methods for studying memory T cells and in the design of vaccines are
incrementally establishing vaccines that are capable of generating immune responses and protection
from infection and/or disease against all significant infectious pathogens.
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